

1                    **Unraveling the Molecular Landscape of Congenital**  
2                    **Pseudoarthrosis of the Tibia: Insights from a**  
3                    **Comprehensive Analysis of 162 Proband**

4                    **Guanghui Zhu<sup>1,2,3#</sup>, Nan Li<sup>4#</sup>, Yu Zheng<sup>1,3,5#</sup>, Shun Yao Wang<sup>4</sup>, Ge Yang<sup>1,2,3</sup>, Yaoxi Liu<sup>1,2,3</sup>,**  
5                    **Zongren Xu<sup>4</sup>, Hui Huang<sup>4\*</sup>, Huanhuan Peng<sup>4\*</sup>, Haibo Mei<sup>1,2,3\*</sup>**

6                    <sup>1</sup>Department of Pediatric Orthopedics, Hunan Children's Hospital, Hunan 410007, PR China

7                    <sup>2</sup>Hunan Provincial Key Laboratory of Pediatric Orthopedics, Hunan 410007, PR China

8                    <sup>3</sup>The school of pediatrics, University of South China, Hunan 410007, PR China

9                    <sup>4</sup>BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China

10                  <sup>5</sup> Hunan Children's Research Institute (HCRI), Hunan Children's Hospital, Hunan 410007, PR  
11                  China

12

13

14

15

16                  # Guanghui Zhu, Nan Li and Yu Zheng contributed equally to this article.

17                  \* Corresponding authors:

18                  Hui Huang, BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China. E-mail address:

19                  huanghui@genomics.cn

20                  Huanhuan Peng, BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China. E-mail address:

21                  penghh@genomics.cn;

22                  Haibo Mei, Hunan Key Laboratory of Pediatric Orthopedics; Department of Pediatric

23                  Orthopedics, Hunan Children's Hospital; The school of pediatrics, University of South China

24                  Hunan 410000, PR China E-mail address: meihaibo@sohu.com;

25

26                  Fundings: Opening fundings of Hunan Provincial Key Laboratory of Pediatric Orthopedics

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41                  **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 42 **Abstract**

43 Congenital pseudarthrosis of the tibia (CPT, HP:0009736),  
44 commonly known as bowing of the tibia, is a rare congenital  
45 tibia malformation characterized by spontaneous tibial fractures  
46 and the difficulty of reunion after tibial fractures during early  
47 childhood, with a very low prevalence between  
48 1/250,000~1/140,000. While 80%–84% of CPT cases present  
49 with neurofibromatosis type 1, caused by the mutations in *NF1*,  
50 the underlying cause of CPT is still unclear. Considering the  
51 congenital nature and the low prevalence of CPT, we hypothesized  
52 that the rare genomic mutations may contribute to CPT. In this  
53 study, we conducted whole exome sequencing on 159 patients  
54 with CPT and full-length transcriptome sequencing on an  
55 additional 3 patients with CPT. The data analysis showed there  
56 were 179 significantly up-regulated genes which were enriched in  
57 40 biological processes among which 21 biological processes hold  
58 their loss of function (LoF) excesses between 159 cases against  
59 208 controls from 1000 Genomes Project. From those 21  
60 biological processes with LoF excesses, there were 259 LoF-  
61 carried genes among which 40 genes with 56 LoF variations in 63  
62 patients were enriched in osteoclast differentiation pathway  
63 (hsa04380) with its 3 directly regulated pathways including

64 MAPK signaling pathway (hsa04010), calcium signaling pathway  
65 (hsa04020) and PI3K-Akt signaling pathway (hsa04151), as well  
66 as fluid shear stress and atherosclerosis pathway (hsa05418)  
67 while 12 patients carried 9 LoF variations in the *NF1* gene. The  
68 rare LoF variations in these pathways accounted for ~39.6% of  
69 this CPT cohort. These findings shed light on the novel genetic  
70 mutations and molecular pathways involved in CPT, providing a  
71 new framework for understanding how the genetic variations  
72 regulate the biological processes in the pathology of CPT and  
73 indicating potential next directions to further elucidate the  
74 pathogenesis of CPT.

## 75 **Introduction**

76 Congenital pseudarthrosis of the tibia (CPT) is a rare  
77 orthopedic disease with an incidence between 1 in 140,000 and 1  
78 in 250,000 live births [1]. It is characterized by the pseudarthrosis  
79 or pathological fractures of the anterolateral part of the tibia in  
80 early life, resulting in bowing, narrowing of the medullary canal,  
81 or the presence of a cyst. This condition poses a significant  
82 surgical challenge due to recurrent fractures and the inability to  
83 achieve bone union [2]. Congenital anterolateral bowing of the  
84 tibia is generally considered a precursor of CPT and is commonly

85 associated with neurofibromatosis type 1(NF1), a common  
86 autosomal dominant genetic disorder [3]. Previous research has  
87 reported that 80%–84% of CPT cases present with NF1(NF1-CPT)  
88 in the epidemiology and the genomic mutations in the *NF1* gene  
89 have been linked to CPT in the genomics [4-7]. The double  
90 inactivation model has been proposed as a hypothesis to explain  
91 these associations [8-11] . However, other researchers have  
92 suggested that the molecular pathogenesis of NF1-CPT may not  
93 be entirely explained by second mutations or loss of  
94 heterozygosity of the *NF1* gene [7, 12, 13].

95       Recent investigations have shed light on the molecular basis  
96 of CPT, for example, *NF1* gene has been reported to be involved in  
97 bone remodeling and mineralization [14]. Inhibited bone  
98 formation and stimulated bone resorption have also been  
99 reported in patients with CPT who harbor *NF1* mutations [15].  
100 Furthermore, the involvement of FGFR3 signaling in cartilage-to-  
101 bone transformation for bone repair [16] and the contribution of  
102 vasoactive intestinal peptide through ERK and NF- $\kappa$ B signal  
103 pathways have been implicated in CPT [17]. Differentially  
104 expressed proteins (DEPs) found in serum-derived exosomes of  
105 CPT patients have been shown to inhibit bone formation and  
106 stimulate bone resorption[18] while DEPs from in the tibia

107 periosteum tissues are mainly involved in cell matrix assembly,  
108 cell adhesion, AKT-PI3K signal pathway activation, and vascular  
109 agglutination of CPT patients [19]. These conclusions indicate the  
110 intricate biological processes and molecular regulation pathways  
111 associated with bone homeostasis potentially contribute to CPT  
112 [20-23]. However, a comprehensive understanding of the etiology  
113 of CPT is still elusive due to the rarity of CPT and limited samples  
114 in previous studies.

115 To address this gap, we employed an approach used to  
116 investigate the severe pediatric developmental disorders with a  
117 low prevalence and the complex genetic architecture, aiming to  
118 identify the low-frequency gene mutations in 159 sporadic CPT  
119 patients. This approach have been successful in elucidating the  
120 genetic basis of other neurodevelopmental disorders, including  
121 epilepsy [24-28], craniosynostosis [29-31], autism [32-40] and  
122 congenital heart disease [41-46]. Specially the rare protein-  
123 damaging variations (PDV), particularly loss of function (LoF)  
124 mutations, have been identified a main contributor to congenital  
125 developmental diseases characterized by low prevalence and  
126 early onset. In light of this, we hypothesized that CPT can also be  
127 explained, at least partially, by the rare LoF variants with  
128 incomplete penetrance. To test this hypothesis, we conducted

129 whole exome sequencing (WES) on a substantial cohort of 159  
130 individuals affected by idiopathic CPT. Additionally, we performed  
131 a full-length transcriptome sequencing on 3 CPT patients to  
132 validate the reported biological processes and detect the new  
133 ones associated with CPT.

134 In this study, we present our comprehensive genetic analysis,  
135 aiming to uncover the complex genetic architecture and  
136 molecular mechanism underlying CPT. Our findings have the  
137 potential to enhance the understanding of CPT pathogenesis and  
138 provide valuable guidance for the development of novel  
139 therapeutic approaches targeting the identified genetic factors.

## 140 **Results**

141 To comprehensively explore the genetic basis and biological  
142 processes underlying CPT, a cohort of 159 along with an  
143 additional 3 Chinese Han CPT patients, with an average age of 42  
144 months, were enrolled for WES and full-length transcriptome  
145 sequencing respectively. In the WES, targeted bases in each  
146 sample were sequenced a mean of 136 times by independent  
147 reads, with 98.73% reading 20 or more times. Following variation  
148 calling, a totally of 286,945 single nucleotide polymorphisms  
149 (SNPs) and 27,807 insertions/deletions (InDels) were detected.

150 For the transcriptome sequencing, an average of 4,816,579 reads  
151 with a length of 787 bp were obtained for each sample.

152 **40 bone homeostasis related biological processes were**  
153 **up-regulated in CPT patients**

154 To get insights into the CPT-related pathways, we performed  
155 nanopore sequencing on the periosteum tissues from three CPT  
156 patients against two healthy individuals. The differential  
157 expression analysis of transcriptome identified 179 genes up-  
158 regulated and 134 down-regulated genes excluding *NF1* gene  
159 ( $|\logFC| > 2$ ,  $FDR < 0.01$ ) in patients with CPT (Fig1 a and b).  
160 Functional enrichment analysis of those up-regulated genes  
161 uncovered 40 significantly enriched biological processes  
162 (threshold  $P=0.01$ ). These enriched biological processes  
163 encompassed skeletal system development ( $\log P=-11.96$ ), tissue  
164 remodeling including bone resorption, cell matrix assembly  
165 ( $\log P=-10.37$ ) [47, 48], regulation of cell adhesion ( $\log P=-8.44$ ),  
166 regulation of MAPK cascade [49] ( $\log P=-5.22$ ) and autophagy in  
167 bone metabolism [50, 51], which have been associated with bone  
168 formation and bone remodeling [19, 52-54]. Additional enriched  
169 biological progress included ossification (e.g., bone  
170 mineralization and endochondral ossification) [55], myeloid

171 leukocyte differentiation (e.g., osteoclast differentiation and  
172 osteoclast development) [56, 57], epithelial cell proliferation (e.g.,  
173 angiogenesis) [58-61], inorganic ion homeostasis [62, 63],  
174 regulation of hormone levels [64, 65], negative regulation of  
175 response to external stimulus [57, 66], Vitamin D receptor  
176 pathway [67-69], cell migration and chemotaxis [70] (Fig.1.c and  
177 supplementary table 1, threshold  $P = 0.05/100 = 5e-4$  by  
178 Bonferroni correction). Some of these processes have been  
179 reported in the DEPs of CPT patients [18, 19, 53] and also known  
180 to play crucial important role in the metabolism of bone  
181 homeostasis. The enriched biological processes identified in the  
182 transcriptome analysis provide a comprehensive reflection of the  
183 etiology of CPT.

## 184 **21 of 40 biological processes beared the LoF excesses in** 185 **CPT patients**

186 Considering the rare prevalence and early onset of CPT, we  
187 postulate that some or all of the 40 biological processes may bear  
188 a significant burden of rare LoF mutations if they contribute to  
189 CPT pathogenesis. To test this hypothesis, we analyzed the genetic  
190 burden of LoF variations from WES data. After variation calling  
191 and filtering, 1,174 confidant LoF single nucleotide variants (SNVs)



192 in 1,037 genes (an average of 7.38 mutations per case with a  
193 mutation rate of  $4.34e-9$ ) were selected for the burden test  
194 between 159 CPT cases and 208 healthy Chinese Han controls  
195 from the 1000 Genomes Project. Among all the 40 significantly  
196 enriched and up-regulated biological processes in transcriptome,  
197 21 processes showed LoF excesses under the threshold  $P < 0.01$   
198 and  $OR > 10$  (Fig2, Table 1), indicating their potential relevance to  
199 CPT. Additionally, the burden test of rare LoF mutations showed  
200 no significant excess of LoF (Bonferroni corrected threshold P-  
201 value  $0.05/1,217=4.1e-5$ ) for each gene except for *NF1* ( $p=$   
202  $5.61357e-05$ ) which was reported in the previous studies [4, 7].  
203 This result suggests that the 21 CPT-related candidate biological  
204 processes, which exhibit a significant rare LoF excess, cannot be  
205 detected by the burden test for single gene. Furthermore, the  
206 other 19 biological processes significantly up-regulated in the  
207 transcriptome and enriched in the Gene Ontology (GO) database  
208 did not show a rare LoF excess, indicating that rare LoF mutations  
209 alone cannot entirely explain the pathogenicity and the complex  
210 genetic architecture of CPT.

211 To assess the association between the 21 biological processes  
212 and the risk of CPT, the odd ratio (OR) is used to quantify the  
213 probability LoF mutations contributing to CPT. We defined the

214 gene set including 5,173 genes from the 21 biological processes  
215 as the transcriptome high expression (THE). The gene set of  
216 biological process (GO:0008150) in GO includes 19,462 genes  
217 except THE, consisting of 14,254 genes, was referred to as the  
218 non-THE (NTHE). Comparing the OR of NTHE (1.73) between CPT  
219 cases and controls, a substantial increase to 18.29 in THE was  
220 displayed. This substantial rise in odds ratio demonstrates that  
221 the rare LoF excesses from THE significantly correlated with an  
222 increased risk of CPT risk. Ultimately, the specific genes  
223 contributing to CPT were identified as the those overlapping  
224 between the LoF-carrying genes and the THE. This resulted in the  
225 discovery of 151 CPT-contributing genes.

## 226 **Osteoclast differentiation with its regulated pathways** 227 **contributes to CPT pathogenesis**

228 To get insight into the molecular mechanism of these 151 CPT-  
229 contributing genes, they were queried in the Kyoto Encyclopedia  
230 of Genes and Genomes (KEGG) database for the enrichment that  
231 highlighted the pathway osteoclast differentiation (hsa04380,  
232 logP=-4.83) likely plays a potential role in CPT, along with its 3  
233 regulated pathways including MAPK signaling (hsa04010, logP=-  
234 2.99), calcium signaling (hsa04020, logP=-2.95) and PI3K-Akt

235 signaling (hsa04151,  $\log P = -2.45$ ). it was worth noting that  
236 tuberculosis pathway (hsa05152,  $\log P = -4.59$ ), Chemical  
237 carcinogenesis - DNA adducts pathway (hsa05204,  $\log P = -4.56$ ),  
238 as well as fluid shear stress and atherosclerosis pathway  
239 (hsa05418,  $\log P = -4.57$ ), were also identified (Fig3 a). To validate  
240 these findings, we examined the LoF excesses within these  
241 pathways. The results demonstrated significant LoF excesses in  
242 the MAPK signaling pathway (OR = 26,  $P = 1.45E-9$ ), Tuberculosis  
243 pathway (OR = 12,  $P = 1.37e-4$ ), Chemical carcinogenesis-DNA  
244 adducts pathway (OR=10,  $P = 0.001$ ), PI3K-Akt signaling pathway  
245 (OR = 9,  $P = 1.48e-5$ ), calcium signaling pathway (OR = 7,  $P =$   
246  $2.66e-4$ ), and osteoclast differentiation pathway (OR = 5.5,  $P =$   
247  $0.001$ ) in CPT cases (Fig3 b and Table 2).

248 Consistent with previous findings, the observed involvement  
249 in the osteoclast differentiation pathway and its 3 regulated  
250 pathways (MAPK signaling, calcium signaling and PI3K-Akt  
251 signaling ) support the notion that CPT patients exhibit an  
252 imbalance in the low reparative potential of bone tissue due to the  
253 osteoclast activation prevailing over differentiation of osteoblasts,  
254 progenitor and mesenchymal cells [71]. The regulation of  
255 osteoclast differentiation and activation could become a

256 promising strategy for preventing bone erosion in patients with  
257 CPT [17].

258 *NF1*, a reliable CPT-causing gene reported in previous studies,  
259 is believed to involve disruptions in bone remodeling and vascular  
260 abnormalities. Osteoclasts in *NF1* display enhanced resorption  
261 capacity and aberrant morphology [72]. The disorders of the  
262 Ras/MAPK pathway have an overlapping skeletal phenotype, such  
263 as scoliosis and osteopenia. The Ras proteins regulate cell  
264 proliferation and differentiation. Studies have shown that  
265 individuals carrying *NF1* mutations have osteoclast hyperactivity  
266 and increased bone resorption in the studies [73, 74]. In our study,  
267 *NF1* gene exhibits 9 LoF variations only in 12 patients (7.54%)  
268 with a heterozygous genotype. Alongside *AKT2*, *CD14*, *IL1RAP*,  
269 *MAP3K4*, *MAP3K11*, *RPS6KA1*, *TGFA* and *RASGRP2*, *NF1* was  
270 enriched in the MAPK signaling pathway (logP=-2.99). This  
271 suggests a potential framework for understanding how *NF1*  
272 contribute to the etiology of CPT.

273 Furthermore, *LILRB4*, *LILRB2*, *LILRB1* and *LILRA2* carrying 2  
274 LoFs respectively are enriched in the osteoclast differentiation  
275 pathway along with *AKT2*, *CALCR*, *FCGR3A* and *IFNG*. The complex  
276 of *FCGR3A* and *LILRB1/LILRB2/LILRB4/LILRA2*, known as the  
277 osteoclast-associated receptor (OSCAR), is a regulator of

278 osteoclast differentiation and dendritic cell maturation. It has  
279 been reported to cause skeleton-related phenotypes, such as  
280 abnormal osteoclast differentiation, reduced osteoarthritis  
281 manifestation, decreased chondrocyte apoptosis and abnormal  
282 bone morphology in knockout mice [75]. In osteoclasts, OSCAR is  
283 mediated by the immunoreceptor tyrosine-based activation motif  
284 adaptor protein FcRγ and co-stimulates osteoclasts cultured in an  
285 extracellular matrix or collagen [76]. *CALCR* is involved in  
286 regulating osteoclast-mediated bone resorption and has been  
287 reported to be associated with osteoporosis and bone mineral  
288 density quantitative trait locus 15 (<https://www.genecards.org/>).  
289 *IFNG* suppresses osteoclastogenesis by suppressing TRAF6-  
290 mediated signaling downstream of RANK, the receptor for RANKL  
291 [77]. That is, osteoclastogenesis would increase when the  
292 expression of *IFNG* is down-regulated due to the LoF variations.

293 Additionally, *COL6A5* carrying 2 LoF mutations, accompanied  
294 by *AKT2*, *JAK3*, *NOS3*, *TGFA*, *TLR2*, *SGK2*, *PKN3*, *TNN*, *KRT16* and  
295 *OPRM1*, is enriched in PI3K-Akt signaling pathway (logP = -2.45).  
296 This pathway has been reported to be involved in CPT by  
297 quantitative proteomics analysis [19]. The knockdown of *AKT2*  
298 was reported to suppress osteoclastogenesis through the  
299 PI3K/Akt/GSK3 signaling pathway [78]. Furthermore, alongside

300 *HRC, MST1R, NOS3, P2RX1, TACR2, PPIF* and *TRDN, PLCZ1* carrying  
301 2 LoF mutations is enriched in the calcium signaling pathway  
302 ( $\log P = -2.95$ ). Calcium signaling plays a crucial role in osteocyte  
303 mechanotransduction, as the release of calcium serves as a  
304 powerful second messenger. Calcium provides essential  
305 information for mechanical responses and participates in  
306 downstream regulatory processes [66].

307 Finally, *GSTM4* carrying 2 LoF mutations, along with *AKT2*,  
308 *IFNG, NOS3, PLAT, SELE, ARHGEF2, GSTO1, AKR1C4, AKR1C3, PPIF*  
309 and *SLC26A6*, is enriched in fluid shear stress and atherosclerosis  
310 (has05418). Previous studies have reported the involvement of  
311 osteoclasts and osteoblasts in activating different mechanical  
312 transduction pathways such as fluid shear stress and reported  
313 changings in their differentiation, formation, and functional  
314 mechanism induced by the application of different types of  
315 mechanical stress to bone tissue[79-81].

316 In summary, the osteoclast differentiation pathway, along with  
317 its 3 directly regulated pathways, not only exhibited rare LoF  
318 excesses but also showed shared transcriptome patterns between  
319 CPT cases and controls. These pathways serve as a reliable set of  
320 potential candidate pathways contributing to the etiology of CPT.  
321 Overall, there were 63 patients carrying 40 CPT-contributing

322 genes with 56 LoF variations in the osteoclast differentiation  
323 pathways and their 3 directly regulated pathways (Table 3).

### 324 **Hub genes enriched in hedgehog signaling pathway and** 325 **likely regulate the molecular pathways of CPT**

326 Interestingly, the Protein-protein interaction network analysis  
327 in the 151 CPT-contributing genes indicated that there were 8 hub  
328 genes (*BOC*, *SMO*, *PTCH2*, *ULK4*, *CORIN*, *USH2A*, *F12* and *MAGI3*)  
329 which showed a significant enrichment in hedgehog signaling  
330 pathway (hsa04340, logP= -6.5) and 3 genes *TIRAP*, *CD14* and  
331 *TLR2* in Lipid and atherosclerosis (hsa05417, logP=-6.5). As the  
332 members of Hedgehog signaling pathway, *BOC*, *SMO* and *PTCH2*  
333 respectively carried 1 LoF mutation, and was indicated to be  
334 regulated by the other 5 hub genes in the PPI network. Hedgehog  
335 signaling pathway had been reported play a crucial role in  
336 regulating bone formation and homeostasis[82, 83] and the  
337 premature SHH signaling resulting from disruption of *GPR161*  
338 causes defects in limb and skeletal morphogenesis[84].

### 339 **Discussion**

340 CPT is a rare bone disorder primarily affecting newborns and  
341 characterized by challenging complications such as refracture,

342 tibial non-union, and failed surgery [85]. The underlying  
343 pathophysiology involves excessive osteoclast activity caused by  
344 the fibrous hamartoma surrounding the bone and impaired  
345 osteogenesis and bone morphogenetic protein function, resulting  
346 in frequent tibial fractures, bone atrophy, and compromised bone  
347 remodeling [86]. Neurofibromatosis type 1, with the prevalence  
348 of 1/3,000 [87], is linked to CPT in many cases and contribute to  
349 anterolateral bowing of the tibia, leading to pathologic  
350 fracture. Previous study has claimed the gene *NF1* encodes  
351 neurofibromin, a ubiquitous protein expressed in osteoblasts,  
352 osteoclasts, chondrocytes, fibroblasts and endothelial cells, and  
353 neurofibromin negatively regulates the activity of Ras which  
354 involved in cellular proliferation and differentiation, leading to  
355 the physically preventing bony bridging and endochondral bone  
356 repairing by the recurrent invasion and increased proliferation of  
357 fibrous lesion cells in the cellular deficiencies, suggesting the role  
358 of *NF1* in bone development, homeostatic regulation, and repair  
359 in Neurofibromatosis type 1 [88]. However, the complete  
360 understanding of CPT cannot be fully attributed to the *NF1* gene  
361 within the framework of neurofibromatosis type 1. And other  
362 factors, including intrauterine trauma and generalized metabolic  
363 disturbances at the time of birth, are believed to contribute [89].



364 Recent studies have identified several biological processes, such  
365 as skeletal system development, tissue morphogenesis and cell  
366 differentiation/proliferation, are associated to CPT[18, 19, 53],  
367 these findings suggest the involvement of intricate molecular  
368 processes in which other genes, in cooperation with *NF1*, may  
369 contribute to CPT. However, the precise mechanisms underlying  
370 these effects have not yet been elucidated.

371 In this study, we sequenced the transcriptome of periosteal  
372 tissues from three patients with CPT and two healthy individuals,  
373 and identified 180 up-regulated genes in CPT patients, which  
374 were enriched in 40 biological processes related to bone  
375 homeostasis. These biological processes encompassed skeletal  
376 system development, tissue remodeling (e.g., bone resorption),  
377 cell matrix assembly, regulation of cell adhesion, regulation of the  
378 MAPK cascade and autophagy in bone metabolism. These findings  
379 are consistent with previous studies and provide an overview of  
380 the biological processes likely associated with CPT, despite the  
381 limited number of patient samples included in this analysis.  
382 Furthermore, to gain insight into the effects of genomic LoF  
383 variations on CPT, we performed WES on 159 patients and  
384 observed significant excesses of rare LoF variations in 21 out of  
385 the 40 biological processes. This indicates the rare LoF variations

386 play an important role in CPT-related biological processes. Most  
387 importantly, through gene-pathway enrichment analysis using the  
388 KEGG database, we identified 63 patients carrying 40 genes with  
389 56 LoF variations in the osteoclast differentiation pathway with  
390 its 3 directly regulated pathways (MAPK signaling pathway,  
391 Calcium signaling pathway and PI3K-Akt signaling pathway), as  
392 well as the fluid shear stress and atherosclerosis pathway. This  
393 provides a comprehensive illustration of how rare genomic LoF  
394 variations in the osteoclast differentiation pathways contribute to  
395 the pathological process of CPT.

396 Additionally, we also observed that 19 out of the 40 biological  
397 processes showed significant gene enrichment in the  
398 transcriptome but did not exhibit significant LoF excesses. This  
399 suggests the involvement of other types of genomic mutations  
400 contributing to CPT. For instance, among the CPT patients, apart  
401 from MAPK signaling pathway( $P=3.67e-08$ ), calcium signaling  
402 pathway ( $P=1.58e-10$ ) and PI3K-Akt signaling pathway ( $P=4.15e-$   
403  $10$ ), we found missense mutations exhibited the excesses  
404 specifically in apoptosis pathways ( $P=6.58e-05$ ) and mTOR  
405 signaling pathway ( $P=3.15e-05$ ) which have been confirmed as  
406 the crucial pathways orchestrating the bone resorption in bone  
407 metabolic diseases [90, 91].

408 Compared with the fact that up to 80%-84% of patients with  
409 CPT present with neurofibromatosis type 1, we found NF1 carried  
410 9 LoF mutations in 12 patients, with a prevalence 19% in this  
411 study. This paradox in prevalence suggests some of our 56 LoF  
412 mutations may not directly cause CPT but instead participated in  
413 the regulation of the imbalanced bone homeostasis resulted from  
414 CPT. Furtherly considering the extreme low prevalence of CPT, de  
415 novo mutations would serve as more accurate genomic markers  
416 for the genetic diagnosis of CPT under our current pathway  
417 framework.

418 In summary, our findings highlight that rare genomic LoF  
419 variations in genes involved in osteoclast differentiation and  
420 regulation pathways play crucial role in the pathological process  
421 of CPT. This provides a new framework for understanding how  
422 genetic variations regulate biological processes in the pathology  
423 of CPT.

424

## 425 **Method**

### 426 **Patient Recruitment and study subjects**

427 A consecutive cohort of 165 CPT patients admitted into the  
428 department of Orthopedics of Hunan Children's Hospital from

429 2016 to 2020 was enrolled in this study. For WES, a total of 159  
430 CPT patients, of which 75 cases had been reported in 2019[7],  
431 provided peripheral blood samples for DNA extraction and  
432 sequencing. For the transcriptome sequencing, two normal  
433 periosteal tissues were obtained from healthy children  
434 undergoing surgery for tibial fracture, as well as three diseased  
435 periosteum tissues were obtained from the patients with CPT  
436 during surgery at Hunan Children's Hospital. This study had been  
437 approved by the Ethics Committee of Hunan Children's Hospital,  
438 and informed consent had been obtained from all patients.

## 439 **Transcriptome sequencing by nanopore platform and** 440 **data analysis**

### 441 RNA Extraction from Periosteal Tissue

442 During the surgical procedure, periosteal tissue devoid of bone  
443 needles and encompassing cortical bone was collected and  
444 immediately dissected into small fragments measuring  
445 approximately 200 mg with a diameter of approximately 5 mm.  
446 These fragments were then placed in centrifuge tubes filled with  
447 phosphate-buffered saline (PBS) and thoroughly washed.  
448 Subsequently, they were transferred to cryovials and snap-frozen  
449 in liquid nitrogen for storage. Total RNA extraction from the

450 periosteal tissue was performed using Takara TRIzol reagent  
451 according to the manufacturer's standard protocol. The extracted  
452 RNA was subjected to quality assessment using the IMPLEN Nano  
453 Photometer for spectrophotometric analysis, Nanodrop 2000 for  
454 concentration measurement of RNA samples, Agilent 2100 for  
455 integrity assessment, and agarose gel electrophoresis. One  
456 microgram of purified total RNA with a minimum RNA integrity  
457 number (RIN) value of 6 was reverse transcribed into  
458 complementary DNA (cDNA) using the cDNA-PCR sequencing kit  
459 (SQK-PCS109).

#### 460 Full-Length Transcriptome Sequencing

461 The experimental workflow followed the standard procedure  
462 provided by Oxford Nanopore Technologies (ONT), including  
463 sample quality check, library construction, library quality  
464 assessment, and library sequencing. The total RNA extracted from  
465 periosteal tissue was required to be at least 1.5 µg, suitable for  
466 three library preparations, with a concentration of  $\geq 40$  ng/µl, a  
467 volume of  $\geq 10$  µl, an OD<sub>260/280</sub> ratio between 1.7 and 2.5, an  
468 OD<sub>260/230</sub> ratio between 0.5 and 2.5, and a normal peak at 260  
469 nm absorption. Samples with an RIN value of 6 or higher were  
470 selected for full-length transcriptome sequencing using ONT. The

471 library construction process involved the following steps: First,  
472 oligo dT primers were utilized to anneal with the polyA tail of  
473 mRNA, followed by the addition of reverse transcriptase (RT) to  
474 synthesize the first cDNA strand. Next, specific PCR adapters were  
475 added to both ends of the first cDNA strand, and a 14-cycle cDNA  
476 PCR was performed using LongAmp Tag DNA polymerase (New  
477 England Biolabs, Ipswich) with an extension time of 8 minutes.  
478 This step amplified the double-stranded cDNA using amplification  
479 primers. Subsequently, DNA damage repair and end repair were  
480 conducted using the NEBNext FFPE DNA Repair Mix and NEBNext  
481 Ultra II End Repair/dA-Tailing Module to repair and end-repair  
482 the nucleic acid fragments, followed by A-tailing. The sequencing  
483 adapters were then ligated using the SQK-LSK110 kit (ONT), and  
484 purification was carried out using Agencourt XP beads (Beckman  
485 Coulter, USA). The prepared cDNA library was sequenced using  
486 the Oxford Nanopore PromethION 48 platform (Biomarker,  
487 Beijing).

488 After transcriptome sequencing, we trim the adaptors by  
489 software porechop v0.2.4(<https://github.com/rrwick/Porechop>),  
490 aligned the reads to reference hg19 and quantified gene  
491 expression using the FLAIR software [92]. We identified 179  
492 significantly up-regulated genes and 134 significantly down-

493 regulated genes ( $|\log_{2}FC| > 2$  and  $FDR < 0.01$ ) between CPT cases  
494 and controls using the differential expression analysis module of  
495 the Trinity software [93]. Furthermore, we obtained the  
496 significantly enriched pathways (supplementary table 1) of these  
497 179 up-regulated genes using the Metascape software [94]  
498 (accessed May 2022).

### 499 **WES, variation calling and filtering**

500 Genomic DNA from peripheral blood was extracted using the  
501 standard phenol-chloroform method. The DNA of all 159 CPT  
502 patients was fragmented and the exome was captured using the  
503 Agilent SureSelect Human All Exon V6 kit. The captured DNA  
504 was sequenced with 100 bp pair-end reads using the  
505 BGISEQ2000 platform, following the manufacturer's  
506 instructions. Each sample yielded an average of 13.3 Gb of raw  
507 data with an average depth of 132 and a coverage ratio of  
508 99.84% of the captured target region of 60.46 M. Over 98%  
509 (average ~92.9%) of the bases had a phred quality score  $> 30$ .  
510 For the variation calling, the raw reads were filtered by  
511 SOAPnuke [95] and then mapped to the human genome  
512 reference (UCSC/GRCh37/hg19) using the Burrows-Wheeler  
513 Aligner (BWA-MEM, version 0.7.10) [96]. Variants were called

514 using the Genome Analysis Tool Kit (GATK, version 4.1) [97]. To  
515 validate the accuracy of the variation calling, 208 Chinese Han  
516 individuals from the 1000 Genomes Project were selected as a  
517 control to perform principal component analysis (PCA). This  
518 allowed us to remove the false positive WES variations by setting  
519 genotype quality > 30, the minimum read depth of 20 for each  
520 genotype, and an additional setting of the allele balance of 0.3 for  
521 each heterozygous genotype. Furthermore, all indels with allele  
522 lengths greater than 10 bp were removed. The Variant Effect  
523 Predictor (VEP) [98] was used to annotate and classify all the  
524 variants. Subsequently, the variants were filtered based on their  
525 frequency in public database gnomAD  
526 (<https://gnomad.broadinstitute.org/>) and the bi-allelic LoF  
527 variants (frameshift\_variant, splice\_acceptor\_variant,  
528 splice\_donor\_variant, start\_lost, stop\_gained and stop\_lost) with  
529 MAF < 0.001 were retained.

### 530 **LoF excess test for pathway gene sets**

531 After obtaining the VCF file of LoF variations, the software  
532 rvtest[99] was used to test the LoF excess for each gene set from  
533 the biological processes or KEGG pathways. The burden test was  
534 performed using the CMC model, with a control population



535 consisting of 208 Chinese Han individuals selected from the  
536 1000 Genomes Project as the control population against the 159  
537 patients with CPT. The VCF files containing the variations  
538 information of both the 159 patients and the 208 control  
539 individuals were at the service for request. The genes  
540 corresponding to the biological processes were obtained from  
541 <http://amigo.geneontology.org/amigo/term/GO:0008150>, with  
542 the organism selected as Homo sapiens. The genes of KEGG  
543 pathways were downloaded from  
544 <https://www.genome.jp/kegg/>.

545

## 546 **Tables**

547 Table 1. LoF excess in 21 biological processes enriched in the GO  
548 database

<b>Go Term</b>	<b>Num.L oF</b>	<b>Num.C ase</b>	<b>Num.C trl</b>	<b>O R</b>	<b>P.fish er</b>	<b>P.rvte st</b>
regulation_of_MAPK_cascade_GO:0043408	34	35	1	35	4.13E- 13	2.81E- 12
monoatomic_ion_homeostasis_GO:0050801	34	33	0	33	2.74E- 12	5.69E- 12
regulation_of_hormone_levels_GO:0010817	27	29	0	29	1.13E- 10	1.38E- 10
inflammatory_response_GO:0006954	33	28	0	28	2.81E- 10	1.38E- 10
positive_regulation_of_cytokine_production_GO:001819	27	24	0	24	1.03E- 08	3.14E- 09
ossification_GO:0001503	18	23	0	23	2.50E- 08	1.46E- 08

regulation_of_monoatomic_ion_transport_GO:0043269	42	35	2	17.5	4.86E-12	3.20E-11
myeloid_leukocyte_differentiation_GO:0002573	13	17	0	17	4.45E-06	1.37E-06
regulation_of_bone_resorption_GO:0045124	11	16	0	16	1.03E-05	2.89E-06
regulation_of_cell_growth_GO:0001558	16	16	0	16	1.03E-05	2.89E-06
response_to_lipopolysaccharide_GO:0032496	15	16	1	16	1.03E-05	1.51E-05
ameboidal-type_cell_migration_GO:0001667	15	14	1	14	5.41E-05	6.58E-05
regulation_of_binding_GO:0051098	14	14	0	14	5.41E-05	1.28E-05
negative_regulation_of_locomotion_GO:0040013	27	27	2	13.5	6.33E-09	1.73E-08
negative_regulation_of_transport_GO:0051051	36	36	3	12	1.59E-11	2.94E-11
cell_morphogenesis_GO:0000902	23	23	2	11.5	1.94E-07	3.62E-07
skeletal_system_development_GO:0001501	26	23	2	11.5	1.94E-07	3.62E-07
regulation_of_T_cell_proliferation_GO:0042129	10	11	1	11	0.000612	0.00059
response_to_nutrient_GO:0007584	9	11	0	11	0.000612	0.00017
negative_regulation_of_response_to_external_stimulus_GO:0032102	24	21	2	10.5	1.03E-06	7.66E-07
B_cell_mediated_immunity_GO:0019724	10	10	0	10	0.001348	0.00017
extracellular_matrix_organization_GO:0030198	36	36	4	9	1.24E-10	2.77E-10
multicellular_organismal_homeostasis_GO:0048871	32	35	4	8.75	2.85E-10	6.09E-10
autophagy_GO:0006914	16	17	2	8.5	4.03E-05	3.06E-05
positive_regulation_of_cold-induced_thermogenesis_GO:0120162	6	8	0	8	0.011904	0.001072
positive_regulation_of_hydrolase_activity_GO:0051345	38	40	5	8	1.75E-11	4.54E-11
positive_regulation_of_cell_development_GO:0010720	22	19	4	4.75	0.00011	8.60E-05
cell_junction_organization_GO:0034330	18	18	4	4.5	0.000217	0.000171

heterotypic_cell-cell_adhesion_GO:0034113	5	4	1	4	0.1707	0.0956
					59	34
endoderm_development_GO:0007492	3	3	0	3	0.3202	0.0466
					44	8
tissue_remodeling_GO:0048771	3	3	1	3	0.3202	0.1986
					44	17
regulation_of_homotypic_cell-cell_adhesion_GO:0034110	2	2	0	2	0.5810	0.1048
					98	16
regulation_of_p38MAPK_cascade_GO:1900744	2	2	0	2	0.5810	0.1048
					98	16
regulation_of_SMAD_protein_signal_transduction_GO:0060390	1	2	0	2	0.5810	0.1048
					98	16
developmental_pigmentation_GO:0048066	3	3	2	1.5	0.6560	0.4486
					41	44
innervation_GO:0060384	1	1	0	1	1	0.2520
						78

549

550 Table 2. KEGG pathway enrichment of THE suffering from LoF

551 variations

Category	Term	Description	LogP	Log(q-value)	InTerm
KEGG Pathway	hsa04380	Osteoclast differentiation	-4.83279	-2.616	8/128
KEGG Pathway	hsa05152	Tuberculosis	-4.58891	-2.616	9/180
KEGG Pathway	hsa05418	Fluid shear stress and atherosclerosis	-4.5734	-2.616	8/139
KEGG Pathway	hsa05204	Chemical carcinogenesis - DNA adducts	-4.56047	-2.616	6/69
KEGG Pathway	hsa04010	MAPK signaling pathway	-2.99947	-1.453	9/294
KEGG Pathway	hsa04020	Calcium signaling pathway	-2.95648	-1.451	8/240
KEGG Pathway	hsa04151	PI3K-Akt signaling pathway	-2.45406	-1.112	9/354
KEGG Pathway	hsa00280	Valine, leucine and isoleucine degradation	-2.09919	-0.836	3/48
KEGG Pathway	hsa04750	Inflammatory mediator regulation of TRP channels	-2.00287	-0.799	4/98

552

553 Table 3. The list of CPT-causing LoF variations

C H R	PO S	R EF	A L T	Consequence	Sy mb ol	Biotype	gnom	HGVS <sub>c</sub>	HGVS <sub>p</sub>
							AD_E AS_A F		
1	268 572 34	A	G	splice_acceptor_v ariant&NMD_transc ript_variant	RP S6 KA 1	nonsense _mediate d_decay	0	ENST00000525 525.1:c.64- 2A>G	.



	123			frameshift_variant	TR	protein_coding	0.0002	ENST000003334	ENSP000003333
6	702	CT	C	&splice_region_variant	DN	oding	441	268.4:c.1186del	984.4:p.Lys396
	514								AsnfsTer27
	154				OP	protein_coding	0.0002	ENST000003337	ENSP000003338
6	567	C	T	stop_gained	RM	oding	719	049.4:c.1201C>	381.4:p.Arg401
	863				1			T	Ter
	161				MA	protein_coding	0.0001	ENST000003348	
6	507	T	C	splice_donor_variant	P3	oding	679	824.7:c.2556+2	.
	701				K4			T>C	
	931				CA	protein_coding	0.0007	ENST000003359	ENSP000003352
7	252	C	T	start_lost	LC	oding	849	558.2:c.3G>A	561.2:p.Met1?
	41				R				
		G							
	150	G						ENST00000297	
7	708	T	G	splice_donor_variant&intron_variant	NO	protein_coding	0	494.3:c.2984+3	.
	074	A			S3			_2984+6del	
		A							
	420							ENST00000220	ENSP00000220
8	378	G	T	stop_gained	PL	protein_coding	5.44E-05	809.4:c.1176C>	809.4:p.Tyr392
	06				AT			A	Ter
	131							ENST00000291	ENSP00000291
9	467	C	T	stop_gained	PK	protein_coding	0	906.4:c.229C>	906.4:p.Arg77T
	786				N3			T	er
	514				AK	protein_coding	0	ENST00000380	ENSP00000369
1	474	C	T	stop_gained	R1	oding	0	554.3:c.748C>	927.3:p.Arg250
0	4				C3			T	Ter
	525	A			AK	protein_coding	5.44E-05	ENST00000263	ENSP00000263
1	501	A	A	frameshift_variant	R1	oding	05	126.1:c.738del	126.1:p.Lys247
0	3	G			C4				AsnfsTer8
	711	A			TA	protein_coding	0.0003	ENST00000373	ENSP00000362
1	758	A	A	frameshift_variant	CR	oding	262	306.4:c.214del	403.4:p.Ile72SerfsTer53
0	65	T			2				
	811							ENST00000225	
1	112	A	T	splice_acceptor_variant	PPI	protein_coding	0.0003	174.3:c.316-	.
0	41				F		81	2A>T	
	106	A			GS	protein_coding	5.44E-05	ENST00000369	ENSP00000358
1	025	A	A	frameshift_variant	TO	oding	05	710.4:c.427del	724.4:p.Leu143
0	900	C			1				SerfsTer12
	645				RA	nonsense		ENST00000445	
1	079	T	C	splice_acceptor_variant&NMD_transcript_variant	SG	_mediate	0.0001	445.1:c.372-	.
1	23				RP	d_decay	852	2A>G	
					2				

1	653				MA	nonsense	0.0002	ENST00000524	ENSP00000431
1	747	G	A	stop_gained&NMD	P3	_mediate	0.0002	848.1:c.556C>	506.1:p.Gln186
1	90			_transcript_variant	K1	d_decay	229	T	Ter
1	188				PL	protein_c	0.0002	ENST00000266	
2	546	C	T	splice_donor_varia	CZ	oding	179	505.7:c.949+1	.
2	25			nt	1			G>A	
1	188				PL	processed	0.0002	ENST00000541	
2	903	C	G	splice_donor_varia	CZ	_transcri	721	109.1:n.235+1	.
2	16			nt&non_coding_tra	1	pt		G>C	
1	685				IFN	protein_c	0	ENST00000229	ENSP00000229
2	491	G	A	stop_gained	G	oding	0	135.3:c.484C>	135.3:p.Arg162
2	50							T	Ter
1	380				P2	protein_c	0	ENST00000225	ENSP00000225
7	691	G	A	stop_gained	RX	oding	0	538.3:c.538C>	538.3:p.Arg180
7	2				1			T	Ter
1	294	CT			NF	protein_c	0	ENST00000356	ENSP00000348
7	969	G	C	frameshift_variant	1	oding	0	175.3:c.499_50	498.3:p.Cys167
7	23	TT						2del	GlnfsTer10
1	294				NF	protein_c	0	ENST00000356	ENSP00000348
7	970	C	T	stop_gained	1	oding	0	175.3:c.574C>	498.3:p.Arg192
7	03							T	Ter
1	295				NF	protein_c	5.44E-	ENST00000356	ENSP00000348
7	333	C	T	stop_gained	1	oding	05	175.3:c.1318C>	498.3:p.Arg440
7	15							T	Ter
1	295				NF	protein_c	0	ENST00000356	ENSP00000348
7	534	C	T	stop_gained	1	oding	0	175.3:c.2041C>	498.3:p.Arg681
7	92							T	Ter
1	295				NF	protein_c	0	ENST00000356	ENSP00000348
7	574	G	A	splice_donor_varia	1	oding	0	175.3:c.3113+1	.
7	01			nt				G>A	
1	295				NF	protein_c	0	ENST00000356	ENSP00000348
7	629	C	T	stop_gained	1	oding	0	175.3:c.3916C>	498.3:p.Arg130
7	81							T	6Ter
1	295				NF	protein_c	0	ENST00000356	ENSP00000348
7	761	C	T	stop_gained	1	oding	0	175.3:c.4084C>	498.3:p.Arg136
7	11							T	2Ter
1	296				NF	protein_c	0	ENST00000356	ENSP00000348
7	793	C	T	stop_gained	1	oding	0	175.3:c.7486C>	498.3:p.Arg249
7	66							T	6Ter
1	296				NF	protein_c	0	ENST00000356	ENSP00000348
7	843	C	T	stop_gained	1	oding	0	175.3:c.7846C>	498.3:p.Arg261
7	26							T	6Ter

1	397	A			KR	protein_c		ENST00000301	ENSP00000301
7	684	CT	A	frameshift_variant	T16	oding	0	653.4:c.475_47	653.3:p.Ser159
	64							6del	Ter
1	397		G		KR	protein_c		ENST00000301	ENSP00000301
7	684	G	C	frameshift_variant	T16	oding	0	653.4:c.473_47	653.3:p.Ser159
	67		A					4insTG	AlafsTer17
1	179				JA	protein_c		ENST00000458	
9	552	C	T	splice_acceptor_v	K3	oding	0	235.1:c.-13-	.
	40			ariant				1G>A	
1	407				AK	protein_c		ENST00000579	ENSP00000471
9	408	G	A	stop_gained	T2	oding	0	047.1:c.1270C>	369.1:p.Arg424
	62							T	Ter
1	496				HR	protein_c		ENST00000252	ENSP00000252
9	578	G	A	stop_gained	C	oding	0	825.4:c.649C>	825.3:p.Arg217
	46							T	Ter
1	547	G			LIL	protein_c		ENST00000314	ENSP00000319
9	785	TT	G	frameshift_variant	RB	oding	0	446.5:c.1748_1	960.5:p.Glu583
	81				2			749del	AlafsTer4
1	547				LIL	protein_c		ENST00000314	ENSP00000319
9	785	CT	C	frameshift_variant	RB	oding	0	446.5:c.1744del	960.5:p.Arg582
	86				2				GlyfsTer68
1	550		C		LIL	protein_c		ENST00000251	ENSP00000251
9	863	C	G	frameshift_variant	RA	oding	0	376.3:c.511_51	376.3:p.His171
	56		T		2			2insGT	ArgfsTer16
1	550	T			LIL	protein_c		ENST00000251	ENSP00000251
9	863	G	T	frameshift_variant	RA	oding	0	376.3:c.514_51	376.3:p.Ala172
	58		C		2			5del	ProfsTer27
1	551				LIL	protein_c	0.0007	ENST00000324	ENSP00000315
9	436	G	A	stop_gained	RB	oding	068	602.7:c.582G>	997.7:p.Trp194
	09				1			A	Ter
1	551				LIL	protein_c	0.0001	ENST00000324	ENSP00000315
9	466	G	A	stop_gained	RB	oding	643	602.7:c.1559G	997.7:p.Trp520
	27				1			>A	Ter
1	551	A		frameshift_variant	LIL	protein_c	0.0004	ENST00000270	
9	792	G	A	&splice_region_var	RB	oding	92	452.2:c.1200+1	.
	43			iant	4			del	
1	551				LIL	protein_c	0.0005	ENST00000270	
9	792	T	A	splice_donor_varia	RB	oding	468	452.2:c.1200+2	.
	46			ant	4			T>A	
2	421	A			SG	protein_c	5.44E-	ENST00000341	ENSP00000340
0	950	C	A	frameshift_variant	K2	oding	05	458.4:c.115_11	608.4:p.Pro39A
	65	C						6del	snfsTer17

555 **Figure Legends**

556 Fig1. Identification of differentially expressed genes associated  
557 with CPT in the transcriptome sequencing (a) Volcano plot for the  
558 comparison between the 3 CPT (JG159\_nonNF1, JG250\_NF1 and  
559 JG252\_NF1) and 2 healthy individuals (GDZ001\_Control and  
560 GDZ002\_Control). The cutoff values fold change  $>2$  and  $FDR < 0.01$   
561 were utilized to identify differentially expressed genes. Non-  
562 changed genes were shown in black color. Red color is indicative  
563 of the up-regulated genes and the down-regulated genes. (b)  
564 Heatmap plot of differentially expressed genes. The Pearson  
565 correlation distance metric and the average linkage clustering  
566 algorithm were used. (c) the GO enrichment of the 179 up-  
567 regulated genes in the transcriptome. X-axis indicates the  $-\log(P)$   
568 in which  $P$  is the probability that the genes are enriched in the  
569 biological process in GO database. Here the threshold of  $-\log(P)$  is  
570 set as 2, indicating the  $P$  value 0.01.

571 Fig2. The 179 up-regulated genes in patients with CPT  
572 significantly enriched in 40 biological processes in the GO  
573 biological processes (the Bonferroni corrected  $P = 0.05/100 = 5e-4$ )  
574 among which 21 revealed the LoF excesses (under the criteria  
575  $OR > 10$  and  $P > 0.01$ ). X-axis indicates the biological processes  
576 from GO database and Y-axis indicates the odd ratio (OR) that the



577 LoF mutations enrich in the biological process between 159 CPT  
578 cases and 208 controls. The number above the bar in each process  
579 is the P values indicating the enrichment of LoF mutations in this  
580 process.

581 Fig3. The KEGG pathway enrichment analysis and the LoF  
582 excesses of the transcriptome high expression (THE) gene set  
583 suffering from rare genomic LoF variations. (a) The KEGG  
584 enrichment of THE carrying the LoF mutations. X-axis indicates  
585 the  $-\log(P)$  in which P is the probability that the genes are  
586 enriched in the pathway. Here the threshold of  $-\log(P)$  is set as 2,  
587 indicating the P value 0.01. (b) the LoF excesses of the significant  
588 KEGG pathways enriched by THE. X-axis indicates the pathways  
589 from KEGG database and Y-axis indicates the odd ratio(OR) that  
590 the LoF mutations enrich in the pathway between 159 CPT cases  
591 and 208 controls. The numbers above the bars are the  $-\log(P)$  in  
592 which P indicate the enrichment of LoF mutations in the pathway.  
593 Here the threshold of  $-\log(P)$  is 2, indicating the threshold P 0.01.

594

### 595 **Data availability**

596 Both RNA-seq and WES data are at the service for request.

## 597 **Authors information**

598 Hui Huang, Huanhuan Peng and Haibo Mei conceived and  
599 designed the study. Guanghui Zhu and Yu Zheng collected the  
600 samples and performed the experimental analysis. Nan Li  
601 performed the data analysis and wrote the manuscript. All the  
602 authors read and approved the final manuscript.

## 603 **Declaration of conflicting interests**

604 The authors declare no potential conflicts of interest with  
605 respect to the research, authorship, and/or publication of this  
606 article.

## 607 **Ethics declarations**

608 The experimental protocol was approved by the Research  
609 Ethics Committee of Hunan Children's Hospital. Informed  
610 consent was obtained from every patient.

## 611 **Fundings**

612 Opening fundings of Hunan Provincial Key Laboratory of  
613 Pediatric Orthopedics

## 614 **References**


- 615 [1]. Hefti, F., et al., Congenital pseudarthrosis of the tibia: history, etiology, classification, and  
616 epidemiologic data. *J Pediatr Orthop B*, 2000. 9(1): p. 11-5.
- 617 [2]. Shannon, C.E., A.J. Huser and D. Paley, Cross-Union Surgery for Congenital Pseudarthrosis of the  
618 Tibia. *Children (Basel)*, 2021. 8(7).
- 619 [3]. Han, J., et al., A benign form of congenital anterolateral bowing of the tibia associated with  
620 ipsilateral polydactyly of the hallux: case report and literature review. *Am J Med Genet A*, 2012. 158A(7):  
621 p. 1742-9.
- 622 [4]. Zheng, Y., et al., Case series of congenital pseudarthrosis of the tibia unfulfilling  
623 neurofibromatosis type 1 diagnosis: 21% with somatic NF1 haploinsufficiency in the periosteum. *Hum*  
624 *Genet*, 2022. 141(8): p. 1371-1383.
- 625 [5]. Xu, J., et al., Clinical characteristics and in silico analysis of congenital pseudarthrosis of the tibia  
626 combined with neurofibromatosis type 1 caused by a novel NF1 mutation. *Front Genet*, 2022. 13: p.  
627 991314.
- 628 [6]. Brekelmans, C., et al., Neurofibromatosis type 1-related pseudarthrosis: Beyond the pseudarthrosis  
629 site. *Hum Mutat*, 2019. 40(10): p. 1760-1767.
- 630 [7]. Zhu, G., et al., Identification and characterization of NF1 and non-NF1 congenital pseudarthrosis  
631 of the tibia based on germline NF1 variants: genetic and clinical analysis of 75 patients. *Orphanet J*  
632 *Rare Dis*, 2019. 14(1): p. 221.
- 633 [8]. Lee, S.M., et al., Is double inactivation of the Nf1 gene responsible for the development of  
634 congenital pseudarthrosis of the tibia associated with NF1? *J Orthop Res*, 2012. 30(10): p. 1535-40.
- 635 [9]. El-Hoss, J., et al., A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring  
636 proliferative fibrous tissue and osteoclast-like cells. *J Bone Miner Res*, 2012. 27(1): p. 68-78.
- 637 [10]. Sant, D.W., et al., Evaluation of somatic mutations in tibial pseudarthrosis samples in  
638 neurofibromatosis type 1. *J Med Genet*, 2015. 52(4): p. 256-61.
- 639 [11]. Stevenson, D.A., et al., Double inactivation of NF1 in tibial pseudarthrosis. *Am J Hum Genet*, 2006.  
640 79(1): p. 143-8.
- 641 [12]. Leskelä, H.V., et al., Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast  
642 differentiation and function and altered NF1 gene expression. *Bone*, 2009. 44(2): p. 243-50.
- 643 [13]. Sakamoto, A., et al., Congenital pseudarthrosis of the tibia: analysis of the histology and the NF1  
644 gene. *J Orthop Sci*, 2007. 12(4): p. 361-5.
- 645 [14]. Kamiya, N., et al., Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With  
646 Osteomalacia-like Bone Phenotype. *J Bone Miner Res*, 2017. 32(8): p. 1716-1726.
- 647 [15]. Yang, G., et al., Serum-derived exosomes from neurofibromatosis type 1 congenital tibial  
648 pseudarthrosis impaired bone by promoting osteoclastogenesis and inhibiting osteogenesis. *Exp Biol*  
649 *Med (Maywood)*, 2021. 246(2): p. 130-141.
- 650 [16]. Julien, A., et al., FGFR3 in Periosteal Cells Drives Cartilage-to-Bone Transformation in Bone  
651 Repair. *Stem Cell Reports*, 2020. 15(4): p. 955-967.
- 652 [17]. Qu, H., et al., The effects of vasoactive intestinal peptide on RANKL-induced osteoclast  
653 formation. *Ann Transl Med*, 2021. 9(2): p. 127.
- 654 [18]. Yang, G., et al., Serum-derived exosomes from neurofibromatosis type 1 congenital tibial  
655 pseudarthrosis impaired bone by promoting osteoclastogenesis and inhibiting osteogenesis.  
656 *Experimental Biology and Medicine*, 2021. 246(2): p. 130-141.

- 657 [19]. Liu, Y., et al., New insights into pathogenesis of congenital pseudarthrosis of tibia in children  
658 using periosteum proteomics analysis. *Rapid Commun Mass Spectrom*, 2022. 36(21): p. e9374.
- 659 [20]. Kenkre, J.S. and J. Bassett, The bone remodelling cycle. *Ann Clin Biochem*, 2018. 55(3): p. 308-  
660 327.
- 661 [21]. Salhotra, A., et al., Mechanisms of bone development and repair. *Nature Reviews Molecular Cell  
662 Biology*, 2020. 21(11): p. 696-711.
- 663 [22]. Chan, W., et al., Regulation and Role of Transcription Factors in Osteogenesis. *Int J Mol Sci*, 2021.  
664 22(11).
- 665 [23]. Yahara, Y., et al., The origins and roles of osteoclasts in bone development, homeostasis and repair.  
666 *Development*, 2022. 149(8).
- 667 [24]. Cushion, T.D., et al., De novo mutations in the beta-tubulin gene TUBB2A cause simplified gyral  
668 patterning and infantile-onset epilepsy. *Am J Hum Genet*, 2014. 94(4): p. 634-41.
- 669 [25]. Guella, I., et al., De Novo Mutations in YWHAG Cause Early-Onset Epilepsy. *Am J Hum Genet*,  
670 2017. 101(2): p. 300-310.
- 671 [26]. Kanca, O., et al., De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas,  
672 Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia. *Am J Hum  
673 Genet*, 2019. 105(3): p. 672-674.
- 674 [27]. Schoch, K., et al., A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by  
675 Infantile Epilepsy, Cataracts, and Profound Developmental Delay. *Am J Hum Genet*, 2017. 100(2): p.  
676 343-351.
- 677 [28]. Heyne, H.O., et al., De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet*,  
678 2018. 50(7): p. 1048-1053.
- 679 [29]. Goos, J., et al., A de novo substitution in BCL11B leads to loss of interaction with transcriptional  
680 complexes and craniosynostosis. *Hum Mol Genet*, 2019. 28(15): p. 2501-2513.
- 681 [30]. Ehmke, N., et al., De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with  
682 Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction. *Am J Hum Genet*, 2017. 101(5):  
683 p. 833-843.
- 684 [31]. Timberlake, A.T., et al., De novo mutations in inhibitors of Wnt, BMP, and Ras/ERK signaling  
685 pathways in non-syndromic midline craniosynostosis. *Proc Natl Acad Sci U S A*, 2017. 114(35): p.  
686 E7341-E7347.
- 687 [32]. Awadalla, P., et al., Direct measure of the de novo mutation rate in autism and schizophrenia cohorts.  
688 *Am J Hum Genet*, 2010. 87(3): p. 316-24.
- 689 [33]. O'Roak, B.J., et al., Recurrent de novo mutations implicate novel genes underlying simplex autism  
690 risk. *Nat Commun*, 2014. 5: p. 5595.
- 691 [34]. O'Roak, B.J., et al., Exome sequencing in sporadic autism spectrum disorders identifies severe de  
692 novo mutations. *Nat Genet*, 2011. 43(6): p. 585-9.
- 693 [35]. Uddin, M., et al., Brain-expressed exons under purifying selection are enriched for de novo  
694 mutations in autism spectrum disorder. *Nat Genet*, 2014. 46(7): p. 742-7.
- 695 [36]. Iossifov, I., et al., The contribution of de novo coding mutations to autism spectrum disorder. *Nature*,  
696 2014. 515(7526): p. 216-21.
- 697 [37]. Neale, B.M., et al., Patterns and rates of exonic de novo mutations in autism spectrum disorders.  
698 *Nature*, 2012. 485(7397): p. 242-5.
- 699 [38]. O'Roak, B.J., et al., Sporadic autism exomes reveal a highly interconnected protein network of de  
700 novo mutations. *Nature*, 2012. 485(7397): p. 246-50.


- 701 [39]. Sanders, S.J., et al., De novo mutations revealed by whole-exome sequencing are strongly  
702 associated with autism. *Nature*, 2012. 485(7397): p. 237-41.
- 703 [40]. Sanders, S.J., et al., Multiple recurrent de novo CNVs, including duplications of the 7q11.23  
704 Williams syndrome region, are strongly associated with autism. *Neuron*, 2011. 70(5): p. 863-85.
- 705 [41]. Luo, T., et al., De novo mutations in folate-related genes associated with common developmental  
706 disorders. *Comput Struct Biotechnol J*, 2021. 19: p. 1414-1422.
- 707 [42]. Watkins, W.S., et al., De novo and recessive forms of congenital heart disease have distinct genetic  
708 and phenotypic landscapes. *Nat Commun*, 2019. 10(1): p. 4722.
- 709 [43]. Jin, S.C., et al., Contribution of rare inherited and de novo variants in 2,871 congenital heart disease  
710 probands. *Nat Genet*, 2017. 49(11): p. 1593-1601.
- 711 [44]. Sifrim, A., et al., Distinct genetic architectures for syndromic and nonsyndromic congenital heart  
712 defects identified by exome sequencing. *Nat Genet*, 2016. 48(9): p. 1060-5.
- 713 [45]. Homsy, J., et al., De novo mutations in congenital heart disease with neurodevelopmental and other  
714 congenital anomalies. *Science*, 2015. 350(6265): p. 1262-6.
- 715 [46]. Zaidi, S., et al., De novo mutations in histone-modifying genes in congenital heart disease. *Nature*,  
716 2013. 498(7453): p. 220-3.
- 717 [47]. García-García, A. and I. Martín, Extracellular Matrices to Modulate the Innate Immune Response  
718 and Enhance Bone Healing. *Front Immunol*, 2019. 10: p. 2256.
- 719 [48]. Wang, J., et al., Spatial-Temporal Patterns and Inflammatory Factors of Bone Matrix Remodeling.  
720 *Stem Cells Int*, 2021. 2021: p. 4307961.
- 721 [49]. Ajibade, A.A., H.Y. Wang and R.F. Wang, Cell type-specific function of TAK1 in innate immune  
722 signaling. *Trends Immunol*, 2013. 34(7): p. 307-16.
- 723 [50]. Guo, Y.F., et al., The role of autophagy in bone homeostasis. *J Cell Physiol*, 2021. 236(6): p. 4152-  
724 4173.
- 725 [51]. Montaseri, A., et al., The Role of Autophagy in Osteoclast Differentiation and Bone Resorption  
726 Function. *Biomolecules*, 2020. 10(10).
- 727 [52]. Yang, G., et al., Are Children Suffering From Congenital Pseudarthrosis of the Tibia Associated  
728 With Decreased Bone Strength? *Front Pediatr*, 2022. 10: p. 859580.
- 729 [53]. Li, Z., et al., Differential expression and effect analysis of lncRNA-mRNA in congenital  
730 pseudarthrosis of the tibia. *Front Genet*, 2023. 14: p. 1094298.
- 731 [54]. Tan, Q., et al., The neurofibromatosis type I gene promotes autophagy via mTORC1 signalling  
732 pathway to enhance new bone formation after fracture. *J Cell Mol Med*, 2020. 24(19): p. 11524-11534.
- 733 [55]. Wang, F.S., et al., Biophysical Modulation of the Mitochondrial Metabolism and Redox in Bone  
734 Homeostasis and Osteoporosis: How Biophysics Converts into Bioenergetics. *Antioxidants (Basel)*,  
735 2021. 10(9).
- 736 [56]. Kim, J.M., et al., Osteoblast-Osteoclast Communication and Bone Homeostasis. *Cells*, 2020. 9(9).
- 737 [57]. Delgado-Calle, J. and T. Bellido, The osteocyte as a signaling cell. *Physiol Rev*, 2022. 102(1): p.  
738 379-410.
- 739 [58]. Peng, Y., et al., Type H blood vessels in bone modeling and remodeling. *Theranostics*, 2020. 10(1):  
740 p. 426-436.
- 741 [59]. Tuckermann, J. and R.H. Adams, The endothelium-bone axis in development, homeostasis and  
742 bone and joint disease. *Nat Rev Rheumatol*, 2021. 17(10): p. 608-620.
- 743 [60]. Stucker, S., et al., Bone Angiogenesis and Vascular Niche Remodeling in Stress, Aging, and  
744 Diseases. *Front Cell Dev Biol*, 2020. 8: p. 602269.


- 745 [61]. Diomedede, F., et al., Functional Relationship between Osteogenesis and Angiogenesis in Tissue  
746 Regeneration. *Int J Mol Sci*, 2020. 21(9).
- 747 [62]. Kim, H.D., et al., Biomimetic whitlockite inorganic nanoparticles-mediated in situ remodeling and  
748 rapid bone regeneration. *Biomaterials*, 2017. 112: p. 31-43.
- 749 [63]. Zhang, R., et al., Unique roles of phosphorus in endochondral bone formation and osteocyte  
750 maturation. *J Bone Miner Res*, 2011. 26(5): p. 1047-56.
- 751 [64]. Fischer, V. and M. Haffner-Luntzer, Interaction between bone and immune cells: Implications for  
752 postmenopausal osteoporosis. *Semin Cell Dev Biol*, 2022. 123: p. 14-21.
- 753 [65]. Goltzman, D. and G.N. Hendy, The calcium-sensing receptor in bone--mechanistic and therapeutic  
754 insights. *Nat Rev Endocrinol*, 2015. 11(5): p. 298-307.
- 755 [66]. Qin, L., et al., Molecular mechanosensors in osteocytes. *Bone Res*, 2020. 8: p. 23.
- 756 [67]. Anderson, P.H., Vitamin D Activity and Metabolism in Bone. *Curr Osteoporos Rep*, 2017. 15(5):  
757 p. 443-449.
- 758 [68]. Nakamichi, Y., et al., Mechanisms involved in bone resorption regulated by vitamin D. *J Steroid  
759 Biochem Mol Biol*, 2018. 177: p. 70-76.
- 760 [69]. Zuo, H. and Y. Wan, Nuclear Receptors in Skeletal Homeostasis. *Curr Top Dev Biol*, 2017. 125: p.  
761 71-107.
- 762 [70]. Kim, H.J., et al., Phospholipase D2 controls bone homeostasis by modulating M-CSF-dependent  
763 osteoclastic cell migration and microtubule stability. *Exp Mol Med*, 2022. 54(8): p. 1146-1155.
- 764 [71]. Vykhoanets, E.P., et al., Concentration of several osteotropic growth factors, markers of  
765 osteogenesis and biologically active molecules in the blood serum of patients with congenital  
766 pseudarthrosis of tibia during orthopaedic treatment with combined technologies. *Biomeditsinskaya  
767 Khimiya*, 2018. 64(6): p. 525-533.
- 768 [72]. Heervä, E., et al., Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity,  
769 aberrant morphology, and resistance to serum deprivation. *Bone*, 2010. 47(3): p. 583-90.
- 770 [73]. Stevenson, D.A., et al., Bone resorption in syndromes of the Ras/MAPK pathway. *Clin Genet*, 2011.  
771 80(6): p. 566-73.
- 772 [74]. Sharma, R., et al., Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in  
773 neurofibromin-deficient mice. *Hum Mol Genet*, 2013. 22(23): p. 4818-28.
- 774 [75]. Nedeva, I.R., et al., Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease. *Front Cell  
775 Dev Biol*, 2021. 9: p. 641162.
- 776 [76]. Park, D.R., et al., Osteoclast-associated receptor blockade prevents articular cartilage destruction  
777 via chondrocyte apoptosis regulation. *Nature Communications*, 2020. 11(1): p. 4343.
- 778 [77]. Place, D.E., et al., Osteoclast fusion and bone loss are restricted by interferon inducible guanylate  
779 binding proteins. *Nature Communications*, 2021. 12(1): p. 496.
- 780 [78]. Chen, X., et al., LY3023414 inhibits both osteogenesis and osteoclastogenesis through the  
781 PI3K/Akt/GSK3 signalling pathway. *Bone Joint Res*, 2021. 10(4): p. 237-249.
- 782 [79]. Liu, P., et al., Effects of Mechanical Stress Stimulation on Function and Expression Mechanism of  
783 Osteoblasts. *Front Bioeng Biotechnol*, 2022. 10: p. 830722.
- 784 [80]. Wang, J., Y.X. Sun and J. Li, The role of mechanosensor Piezo1 in bone homeostasis and  
785 mechanobiology. *Dev Biol*, 2023. 493: p. 80-88.
- 786 [81]. Ma, Q., et al., Significance of mechanical loading in bone fracture healing, bone regeneration, and  
787 vascularization. *J Tissue Eng*, 2023. 14: p. 20417314231172573.
- 788 [82]. Zhou, H., et al., Research progress on the hedgehog signalling pathway in regulating bone formation


- 789 and homeostasis. *Cell Prolif*, 2022. 55(1): p. e13162.
- 790 [83]. Wang, H., et al., Hedgehog signaling orchestrates cartilage-to-bone transition independently of  
791 Smoothed. *Matrix Biol*, 2022. 110: p. 76-90.
- 792 [84]. Hwang, S.H., et al., The G protein-coupled receptor Gpr161 regulates forelimb formation, limb  
793 patterning and skeletal morphogenesis in a primary cilium-dependent manner. *Development*, 2018.  
794 145(1).
- 795 [85]. Cai, W., Y. Su and G. Nan, Novel method for the treatment of congenital pseudarthrosis of the tibia  
796 using the gastrocnemius flap: A preliminary study. *J Child Orthop*, 2022. 16(3): p. 167-173.
- 797 [86]. Siebert, M.J. and C.A. Makarewich, Anterolateral Tibial Bowing and Congenital Pseudoarthrosis  
798 of the Tibia: Current Concept Review and Future Directions. *Curr Rev Musculoskelet Med*, 2022.  
799 15(6): p. 438-446.
- 800 [87]. Friedman, J.M., Epidemiology of neurofibromatosis type 1. *Am J Med Genet*, 1999. 89(1): p. 1-6.
- 801 [88]. Schindeler, A. and D.G. Little, Recent insights into bone development, homeostasis, and repair in  
802 type 1 neurofibromatosis (NF1). *Bone*, 2008. 42(4): p. 616-622.
- 803 [89]. Banchhor, H. and V. Chimurkar, Congenital Pseudoarthrosis of the Tibia: A Narrative Review.  
804 *Cureus*, 2022. 14(12): p. e32501.
- 805 [90]. Ru, J.Y. and Y.F. Wang, Osteocyte apoptosis: the roles and key molecular mechanisms in  
806 resorption-related bone diseases. *Cell Death Dis*, 2020. 11(10): p. 846.
- 807 [91]. Wang, S., et al., The Role of Autophagy and Mitophagy in Bone Metabolic Disorders. *International*  
808 *Journal of Biological Sciences*, 2020. 16(14): p. 2675-2691.
- 809 [92]. Tang, A.D., et al., Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic  
810 leukemia reveals downregulation of retained introns. *Nature Communications*, 2020. 11(1): p. 1438.
- 811 [93]. Haas, B.J., et al., De novo transcript sequence reconstruction from RNA-seq using the Trinity  
812 platform for reference generation and analysis. *Nature Protocols*, 2013. 8(8): p. 1494-1512.
- 813 [94]. Zhou, Y., et al., Metascape provides a biologist-oriented resource for the analysis of systems-level  
814 datasets. *Nat Commun*, 2019. 10(1): p. 1523.
- 815 [95]. Chen, Y., et al., SOAPnuke: a MapReduce acceleration-supported software for integrated quality  
816 control and preprocessing of high-throughput sequencing data. *Gigascience*, 2018. 7(1): p. 1-6.
- 817 [96]. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform.  
818 *Bioinformatics*, 2009. 25(14): p. 1754-60.
- 819 [97]. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-  
820 generation DNA sequencing data. *Genome Res*, 2010. 20(9): p. 1297-303.
- 821 [98]. McLaren, W., et al., The Ensembl Variant Effect Predictor. *Genome Biol*, 2016. 17(1): p. 122.
- 822 [99]. Zhan, X., et al., RVTESTS: an efficient and comprehensive tool for rare variant association analysis  
823 using sequence data. *Bioinformatics*, 2016. 32(9): p. 1423-1426.
















# Color Key



-4 0 4  
Value

samples vs. features  
diffExpr.P0.001\_C2.matrix.log2.centered

